Glaucoma treatment is typically life long and requires multiple drops daily. Many practitioners fail to take into account the effect this chronic therapy has on the cornea. This lecture will help optometrists identify dry eye disease in glaucoma patients and provide insight into treatment options for this demographic.

Almost 900 attended our event and we received amazing feedback!

Feedback from anonymous survey:

• very informational about different PF options available

• Great talk and speaker is very knowledgeable!

• I appreciated the speaker showed the science in the application of his diagnosis and treatments.

• Dr. Chaglasion is a great teacher. Would love to hear more from him with glaucoma, etc.

• great review of newest options and meds available

• Appreciate the stress of quality of life for the glaucoma patient!

• Always enjoy lectures by Dr Chaglasian!!

• Dr. Chaglasian presentation was easy to follow and very organized. His slides enhanced his presentation and he clarified the benefits of Preservative Free ocular products in a manner that made good common sense.

• very up to date and informative

• Very helpful in considering preservatives and their affect on the corneal surface.

Speaker: Michael Chaglasian, OD, FAAO

Thank you to Thea for exhibiting at this event.

This event is COPE approved for 1 hour of continuing education.

Laboratoires Théa was among the first eye care companies to introduce preservative-free products. Today, Laboratoires Théa continues its pursuit of solutions that are more efficacious, more ergonomic, and safer. By constantly innovating, Théa has become the market leader in dry eye treatments in Europe.*

 In collaboration with Similasan, a Swiss-based leader in homeopathic OTC products with a focus on eye and ear products, Théa offers its technology and innovative preservative-free products to the US consumer under the iVIZIA brand of products—with iVIZIA lubricant eye drops as the foundation of the product line and formulated to cover the spectrum of dry eye relief.

 *Prescription market data, Sept. 2021 – S01K without cyclosporine.